Development of isoselenazolium chlorides as selective pyruvate kinase isoform M2 inhibitors.

Dimitrijevs, Pavels; Makrecka-Kuka, Marina; Bogucka, Agnieszka; Hyvönen, Marko; Pantelejevs, Teodors; Arsenyan, Pavel

Dimitrijevs, Pavels; Makrecka-Kuka, Marina; Bogucka, Agnieszka; Hyvönen, Marko; Pantelejevs, Teodors; Arsenyan, Pavel.

Afiliação

Dimitrijevs P; Latvian Institute of Organic Synthesis, Aizkraukles 21, LV1006, Riga, Latvia.
Makrecka-Kuka M; Latvian Institute of Organic Synthesis, Aizkraukles 21, LV1006, Riga, Latvia.
Bogucka A; Department of Biochemistry, University of Cambridge, Sanger Building, 80 Tennis Ct Rd, Cambridge, CB2 1GA, UK.
Hyvönen M; Department of Biochemistry, University of Cambridge, Sanger Building, 80 Tennis Ct Rd, Cambridge, CB2 1GA, UK.
Pantelejevs T; Latvian Institute of Organic Synthesis, Aizkraukles 21, LV1006, Riga, Latvia.
Arsenyan P; Latvian Institute of Organic Synthesis, Aizkraukles 21, LV1006, Riga, Latvia. Electronic address: pavel@osi.lv.

Eur J Med Chem ; 257: 115504, 2023 Sep 05.

Article em En | MEDLINE | ID: mdl-37216812

Assuntos

Antineoplásicos; Neoplasias; Humanos; Piruvato Quinase/metabolismo; Cloretos; Neoplasias/metabolismo; Antineoplásicos/farmacologia; Isoformas de Proteínas

Palavras-chave

Cancer; Metabolic reprogramming; Pyruvate kinase M2; Selenium

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias / Antineoplásicos Limite: Humans Idioma: En Revista: Eur J Med Chem Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Letônia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google